B4GALT5抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P09077(B4GALT5 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The B4GALT5 antibody is designed to target β-1.4-galactosyltransferase 5 (B4GALT5), a key enzyme in the glycosylation pathway. B4GALT5 belongs to the β-1.4-galactosyltransferase family, which catalyzes the transfer of galactose from UDP-galactose to terminal N-acetylglucosamine residues on glycoproteins and glycolipids. This post-translational modification is critical for synthesizing complex carbohydrate structures involved in cell-cell interactions, immune responses, and cellular signaling. Dysregulation of B4GALT5 has been implicated in various pathologies, including cancer metastasis, neurodegenerative disorders, and congenital disorders of glycosylation (CDGs).

B4GALT5-specific antibodies are essential tools for studying its expression, localization, and function in biological systems. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding research into its role in disease mechanisms. Commercially available antibodies are typically raised against specific epitopes, such as recombinant protein fragments or synthetic peptides, and validated for specificity using knockout controls or siRNA-mediated silencing. Recent studies highlight B4GALT5's potential as a therapeutic target, particularly in cancers where altered glycosylation promotes tumor progression. However, challenges remain in standardizing antibody performance across experimental models, emphasizing the need for rigorous validation in diverse applications.